Clostridium Difficile Associated Diarrhoea –Problem of Oncological Patient?
Authors:
A. Ligová 1; M. Matuška 1; P. Mrázková 1; D. Feltl 1; J. Mayer 2
Authors place of work:
Klinika onkologická, Fakultní nemocnice Ostrava 2Interní hematoonkologická klinika, Fakultní nemocnice Brno Bohunice
1
Published in the journal:
Klin Onkol 2009; 22(3): 108-116
Category:
Case Reports
Summary
Backgrounds:
Clostridium difficile associated diarrhoea / disease (CDAD) is an inflammatory disease of the colon. It affects patients who have been exposed to wide-spectrum antibiotics and long term in patient care, with immunosuppression. The most difficult form of this disease is manifested as pseudomembranous enterocolitis, it runs fulminantly in significant events. In recent years there has been an increase in the incidence of this disease worldwide. Several serious epidemics caused by virulent strains of Clostridium difficile have been discovered in Western Europe, North America and Asia.
Patients and Methods:
We observed an increased occurrence of this disease at our clinic during 2004–2007. A group of 36 patients with CDAD was analyzed in the article. Patients with different severity courses were identified in the group – from slightly running post antibiotic diarrhoea to serious pancolitis with the manifestation of sepsis and MODS (multiple organ dysfunction syndrome).
Materials and methods:
It is a retrospective analysis of a patients’ group with CDAD.
Results and conclusions:
According to our experience, in the group of oncological patients, post antibiotic clostridia diarrhoea often develops in a very complicated and protracted way. It also affects relatively young patients. Protein malnutrition and febrile neutropenia have a significant occurrence during its genesis. A higher risk of CDAD is found in the group of patients with malignant lymphomas and colorectal malignancy. 20% of our patients did not have any previous ATB exposure, so we can express the theory of oncology therapy as a predisposition factor of CDAD. The CDAD relevance in oncological patients cannot be evaluated according to leukocytosis (a significant part of febrile neutropenia in our group). The disease could require a combined causal therapy and intensive supporting treatment. There is a higher risk of heavy MODS illness course in the group of oncological patients. The article also deals with the case report of one complicated case.
Key words:
colitis – clostridium difficile – pseudomembranous enterocolitis – medical oncology – diarrhoea
Zdroje
1. Aslam S, Musher DM. An Update on Diagnosis, Treatment and Prevention of Clostridium difficile-Associated Disease. Gastroenterol Clin N Am 2006; 35: 315–335.
2. Joyce AM, Burns DL. Reccurent Clostridium difficile colitis Tackling a tenacious nosocomial infection. Postgraduate Medicine. Minneapolis 2002; 112(5): 53.
3. Surawicz CM. Antibiotic – Associated Diarrhea an Pseudomembranous Colitis: Are They Less Common with Poorly Absorbed Antimicrobials? Chemotherapy 2005; 51 (Suppl 1): 81–89.
4. Kelly CP, LaMont JT. Clostridium difficile infection. Ann Rev Med 1998; 49: 375–388.
5. Jedličková A. Antimikrobiální terapie. 1. vyd. Praha: Jesenius Maxdorf 2004.
6. Poutanen SM, Simor AE. Clostridium difficile associated diarrhea in adults. Can Med Assoc J 2004; 171(6): 51–56.
7. Yasin SF, Young-Fadok TM, Zein NN et al. Clostridium difficile-Associated Diarrhea and Colitis. Mayo Clin Proc 2001; 76(7): 725–730.
8. Lee KS, Shin WG, Jang MK et al. Who are Susceptible to Pseudomembranous Colitis Among Patients with Presumed Antibiotic-Associated Diarrhea? Dis Colon Rectum 2006; 49(10): 1552–1558.
9. Riley TV. Epidemic Clostridium difficile. Med J Aust 2006; 185(3): 133–134.
10. Barlett JG. Narrative Review: The New Epidemic of Clostridium difficile – Associated Enteric Disease. Ann Int Med 2006; 145(10): 758–764.
11. Beneš J, Sýkorová B. Kolitida vyvolaná Clostridium difficile. Zpráva z kongresu ICAAC 2006. Klin Mikrobiol Inf Lék 2006; 12(6):247–251.
12. Dettenkofer M, Ebner W, Bertz H et al. Infections Post Transplant. Surveillance of nosocomial infections in adults recipients of allogeneic and autologous bone marrow and perpheral blood sterm-cell transplantation. Bone Marrow Transplant 2003; 31: 795–801.
13. Norén T. Outbreak from a high toxin intruder: Clostridium difficile. Lancet 2005; 366(9491): 1053–1054.
14. Louie TJ. How should we respond to the highly toxogenic NAP1/ribotype 0,27 strain of Clostridium Difficile? Can Med Assoc J 2005; 173(9): 1049–1050.
15. Warny M, Pepin J, Fang A et al. Toxin Production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366(9491): 1079–1084.
16. Deshpande A, Pant C, Jain A et al. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 2008; 24(2): 329–333.
17. von Baum H, Sigge A, Bommer M et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemotherapy 2006; 58: 891–894.
18. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J 2005; 173(9): 1037–1041.
19. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile associated diarrhoea: a systematic review. J Antimicrob Chemotherapy 2003; 51(6): 1339–1350.
20. Louie TJ, Meddings J. Clostridium difficile infection in hospital: risk factors and responses. Can Med Assoc J 2004; 171(1): 45–46.
21. Dial S, Alrasadi K, Manoukian C et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004; 171(1): 33–38.
22. Grover S, Hamilton MJ. Refractory Clostridium difficile associated Diarrhea. Med Gen Med 2007; 9(2): 46.
23. van den Berg RJ, Vaessen N, Endtz HP et al. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile associated diarrhoea in prospective multicentre study. J Med Microbiol 2007; 56: 36–42.
24. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile – associated diarrhea: A review. Arch Int Med Chicago 2001; 161(4): 525–533.
25. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile associated diarrhoea. J Antimicrob Chemotherapy 2004; 54(1): 211–215.
26. Musher DM, Logan N, Hamill R et al. Nitazoxanide for the Treatment of Clostridium difficile Colitis. Clin Infect Dis 2006; 43: 421–427.
27. Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 2006; 35: 85–86.
28. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut 2001; 49(1): 152–153.
29. McFarland L. Meta Analysis of probiotics for the prevention of antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease. Am J Gastroenterol 2006; 101: 812–822.
30. Dendukuri N, Costa V, McGregor M et al. Probiotic therapy for the prevention and treatment of clostridium difficile associated diarrhea: a systematic review. Can Med Assoc J 2005; 173(2): 167–170.
31. Herbrecht R, Nivoix J. Saccharomyces cerevisiae Fungemia: An Adverse Effect of Saccharomyces boulardii Probiotic Administration. Clin Infect Dis 2005; 40(11): 1635–1637.
32. D’Souza AL, Rajkumar C, Cooke J et al. Probiotics in prevention of antibiotic associated diarrhoea: meta analysis. Br Med J 2002; 324(7350): 1361–1364.
33. Greenberger NJ, Sharma P. Update in Gastroenterology and Hepatology. Ann Int Med 2004; 141(5): 374.
34. Ali SO, Welch JP, Dring RJ. Early sugrical Intervention for Fulminant Pseudomembranous Colitis. Am Surg 2008; 74(1): 20–26.
35. Pham M, Lemberg DA, Day AS. Probiotics: sorting the evidence from the myths. Med J Aust 2008; 188(5): 304–308.
36. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via nasogastric tube. Clin Infect Dis 2003; 36(5): 580–585.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2009 Číslo 3
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Evaluation of Aromatase Inhibitors’ Side Effects in Clinical and Experimental Studies
- Clostridium Difficile Associated Diarrhoea –Problem of Oncological Patient?
- Use of PET/CT Examination in Head and Neck Cancer Radiotherapy Planning
- New Radiopharmaceuticals and Positron-emission Tomography Applications at the Masaryk Memorial Cancer Institute in Brno